PICO Portalanswers from OpenAlex
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
PaperCitations, authors & open-access status
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis is a paper indexed in PICO Portal from OpenAlex.
How many citations does Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis have?
PICO Portalcitation count
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis has 462 citations in the OpenAlex counts PICO Portal stores.
When was Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis published?
PICO Portalyear
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis has 2021 year in the PICO Portal index.
What is the open-access status of Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis?
PICO Portaloa status
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis has bronze oa status in the PICO Portal index.
What is the DOI of Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis?
PICO Portaldoi
The DOI for Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis is on the source record.
What is the PMID of Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis?
PICO Portalpmid
The PMID for Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis is on the source record.
What is the OpenAlex record for Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis?
PICO Portalopenalex
The OpenAlex for Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis is on the source record.